Low-dose IL-2 therapy aims either to compensate for this IL-2 deficiency to restore a physiological state or to strengthen the Treg population in order to be more effective in counter-regulating inflammation while avoiding global immunosuppression. The gene discussed is IL2; the disease is hyperinsulinemic hypoglycemia, familial, 4.